Skip to content
City PM
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Opinion
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Opinion
Saturday 03 April 2021 11:31 am

UK reports seven blood clot deaths after Astrazeneca vaccine

By: Poppy Wood

Add as a preferred source on Google

Seven people in the UK have died from blood clots after taking Astrazeneca’s Covid vaccine, Britain’s medicines regulator has confirmed.

The Medicines and Healthcare products Regulatory Agency (MHRA) said it received reports of 30 unusual blood clotting events among patients who have received the Astrazeneca jab, of which seven have died.

It is still unclear whether there is a causal link between the coronavirus vaccine made by the Anglo-Swedish firm and an increased risk of blood clots.

However, the MHRA insisted that the benefits of the jab continue to outweigh any potential risks.

Downing Street said it would keep reviewing the evidence but that its advice and vaccination strategy remained unchanged. “We remain absolutely confident in the vaccine,” a Number 10 spokesperson said.

Earlier this week the European Medicines Agency (EMA) said a causal link was “not proven, but is possible”.

The EMA’s refusal to draw a definitive conclusion on potential risks associated with the vaccine has seen several European countries temporarily ban the jab.

Read more

AviadoBio Presents Positive Preclinical Data for AVB-406 Program in Alzheimer’s Disease and Other Tauopathies at ASGCT 2026

France, Sweden, Finland, Canada and Germany have all recommended that young people, who have a heightened risk of blood clots, should not take the Astrazeneca vaccine.

The Netherlands has limited the vaccine to those aged 60 or older, pending further guidance from European regulators. 

Germany has restricted the use of the vaccine for under-60s, despite the country lagging far behind Europe in its immunisation programme.

Just 12.9 per cent of adults in the country have received their first dose of a Covid vaccine, according to the European Centre for Disease Prevention and Control. In comparison, more than 60 per cent of adults in the UK have received at least a first dose of the jab.

Meanwhile, Norway and Denmark have both suspended the Astrazeneca vaccine altogether, despite it receiving the green light for continued use by the EMA.

Read more

Silence Therapeutics Highlights Follow-Up Data at EHA 2026 Demonstrating Durable Efficacy and Potential Best-in-Class Profile for Divesiran in Polycythemia Vera

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • News

Categories

  • Business
  • Politics

Related Topics

  • AstraZeneca
  • Coronavirus
  • Vaccine

Trending Articles

  • Top Burnham adviser calls for capital gains and inheritance tax hikes

  • A meeting with the breakfast king of Mayfair

  • Housebuilding giants hit with £4.5bn lawsuit for allegedly overcharging buyers

  • As it happened: Stocks jump on defence and metals boost; Oil on track to shed a fifth on US-Iran peace hopes

  • BT tops FTSE 100 after finding new home for international business with Verizon joint venture

More from City PM

  • AviadoBio Presents Positive Preclinical Data for AVB-406 Program in Alzheimer’s Disease and Other Tauopathies at ASGCT 2026

    Business Wire
  • Silence Therapeutics Highlights Follow-Up Data at EHA 2026 Demonstrating Durable Efficacy and Potential Best-in-Class Profile for Divesiran in Polycythemia Vera

    Business Wire
  • Alkermes plc Reports First Quarter 2026 Financial Results

    Business Wire
  • AAHI’s SLA-SE Adjuvant Technology Powers Lilly’s Acquisition of Curevo’s Next-Generation Shingles Vaccine

    Business Wire
  • Alkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Annual Meeting

    Business Wire
  • GSK shares slip after buying US cancer treatment firm Nuvalent for $10.6bn

    Pharma
    GSK logo displayed prominently, signifying the companys presence and relevance in the business and healthcare sectors.
  • IMU Biosciences Selects Waters to Advance Breakthrough AI Immune Mapping Platform to Transform Early Diagnosis, Monitoring, and Precision Medicine

    Business Wire
  • Silence Therapeutics Highlights Recent Business Achievements and Reports First Quarter 2026 Financial Results

    Business Wire

City PM — European politics, business and analysis.

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Topics

  • Business
  • Markets
  • AI
  • Technology
  • Opinion
  • Energy

More

  • Politics
  • Economics
  • Fintech
  • Legal
  • Sport
  • Life

Company

  • About City PM
  • Editorial Policy
  • Corrections
  • Contact
  • Terms of Use
  • Privacy Policy
  • Cookie Policy
© 2026 City PM · Published by CityPM Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
About · Editorial Policy · Corrections · Contact · Privacy